anpac_logo_full color_stacked.png
AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds
18 juin 2021 06h30 HE | Anpac Bio, USA
PHILADELPHIA, June 18, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed
27 mai 2021 06h30 HE | Anpac Bio, USA
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database
25 mai 2021 06h30 HE | Anpac Bio, USA
SAN JOSE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (ANPC) (“AnPac Bio,” the “Company” or “we”), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020
30 avr. 2021 16h45 HE | Anpac Bio, USA
SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss)
30 avr. 2021 08h00 HE | Anpac Bio, USA
SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
22157.jpg
Next Generation Cancer Diagnostics Market Report 2021: Global Next Generation Cancer Diagnostics Market to Grow $15,738.27 Million by 2025, at a CAGR of 22.54%
23 avr. 2021 05h03 HE | Research and Markets
Dublin, April 23, 2021 (GLOBE NEWSWIRE) -- The "Next Generation Cancer Diagnostics Market Research Report by Technology, by Cancer Type, by Function, by Application - Global Forecast to 2025 -...
anpac_logo_full color_stacked.png
AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020
16 avr. 2021 16h15 HE | Anpac Bio, USA
SAN JOSE, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved Performance
09 mars 2021 07h30 HE | Anpac Bio, USA
SAN JOSE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement
05 mars 2021 16h35 HE | Anpac Bio, USA
SAN JOSE, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)
08 févr. 2021 07h00 HE | Anpac Bio, USA
SAN JOSE, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...